LOGIN  |  REGISTER

NexImmune (NASDAQ: NEXI) Stock Quote

Last Trade: US$0.19 -0.02 -9.52
Volume: 14,170
5-Day Change: -36.67%
YTD Change: -91.44%
Market Cap: US$264K

Latest News From NexImmune

GAITHERSBURG, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced the closing of its previously announced registered direct offering of 304,731 shares of its common stock (or common... Read More
GAITHERSBURG, Md., Feb. 02, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that it has entered into a definitive agreement with a single healthcare focused institutional investor for the issuance... Read More
A JDRF funded grant is being used to explore the combination of NexImmune’s antigen specific nanoparticles and an anti-CD3 mAb for prevention and treatment of type 1 diabetes GAITHERSBURG, Md., Oct. 24, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) announces the extension of the research partnership between NexImmune, Yale and JDRF to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3... Read More
GAITHERSBURG, Md., Oct. 19, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that three abstracts have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer... Read More
GAITHERSBURG, Md., Oct. 18, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) (the “Company”) a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that the Board of Directors and stockholders of the Company approved a 1-for-25 reverse... Read More
Company retains core capabilities to continue to advance its nanoparticle injection (AIM INJ) platform and potential product candidates in oncology and autoimmune diseases GAITHERSBURG, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology,... Read More
NEXI-001 data presented at ASCO 2023 demonstrates proof-of-concept in patients with relapsed AML after allogeneic hematopoietic cell transplantation (HCT) and refractory to additional chemotherapy or salvage treatments; one patient continues to show no evidence of disease at nine months Preclinical data demonstrates superior potency and durability when combining T cell engager (TCE) bispecific agents with AIM-expanded... Read More
Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory to salvage therapy NEXI-001 is well tolerated with a favorable safety profile, including no grade > 3 treatment related events as of May 2023 Robust immune response with clinical activity at the highest dose level with one patient achieving no evidence of disease 7 months post-infusion with NEXI-001 Antigen-specific T cells persist in... Read More
AIM nanoparticle approach can identify select EBV-specific T cell defects in patients with multiple sclerosis and may enable killing of EBV+ cells believed to be a contributing factor in this disease Data suggests a potential therapeutic role for AIM multi-antigen-specific products in multiple sclerosis GAITHERSBURG, Md., May 22, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a... Read More
Company has initiated pre-IND discussions with the FDA for its first AIM INJ indication NEXI-001 Phase I data to be presented at ASCO 2023 in June GAITHERSBURG, Md., May 15, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc . (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology,... Read More
GAITHERSBURG, Md., April 26, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today announced that clinical data from its Phase 1/2 dose escalation study of NEXI-001 will be presented in a poster session at the... Read More
Company has initiated pre-IND discussions with the FDA for its first AIM INJ indication NEXI-001 completed enrollment in its final safety cohorts and all patients have been dosed; Company continues to follow patients and will announce data at or around an upcoming scientific conference Company announces executive management changes as part of resource reallocation GAITHERSBURG, Md., March 28, 2023 (GLOBE NEWSWIRE) --... Read More
Tumor Associated Antigen (TAA)-specific AIM ACT CD8 T cells are superior to polyclonal peripheral blood CD4 T cells, naïve CD8 T cells, and bulk CD8 T cells as effectors of BiTE-mediated killing in vivo GAITHERSBURG, Md., Feb. 16, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the... Read More
AIM technology represents a scalable therapeutic platform that has the potential to create new, multi-antigen specific therapies for virally driven infectious diseases, cancers and autoimmune diseases GAITHERSBURG, Md., Jan. 18, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the... Read More
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a collaboration with the National Institute of Neurological Disorders and Stroke (NINDS), a division of the U.S. National Institutes of Health (NIH). The collaboration will focus on... Read More
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Kristi Jones, Chief Executive Officer, will present at the H.C. Wainwright 24 th Annual Global Investment Conference on Monday, September 12 at 11:00 am ET. The webcast will be... Read More
Selexis SA , a JSR Life Sciences company, and NexImmune Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies, announced today that they have signed a service agreement to develop cell lines targeting rare cancers and autoimmune diseases and to advance two HLAs that can be used to expand treatments to more patients. Per the agreement, NexImmune will leverage... Read More
Received U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) submission for NEXI-003, the Company’s first solid tumor product candidate for the treatment of HPV-related cancers Plans to report additional preclinical and IND enabling data for the AIM Injectable platform in 2H22 Clinical updates for the Company’s two lead product candidates in Phase 1/2 clinical trials expected in 4Q22 Company... Read More
First IND for NexImmune’s AIM nanoparticle platform in solid tumors IND clearance enables commencement of a clinical trial to evaluate NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), in patients with relapsed or refractory human papillomavirus (HPV)-related cancers NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a... Read More
Clinical data updates for the Company’s two lead product candidates in Phase 1/2 clinical trials expected in 2H2022 Investigational New Drug (IND) submission for NEXI-003, the Company’s first product for solid tumors, planned for 1H2022 Plans to report additional preclinical and IND enabling data for the AIM Injectable platform in 2H2022 NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a... Read More
A JDRF funded grant will be used to explore the combination of NexImmune’s antigen specific nanoparticles and an anti-CD3 mAb for prevention and treatment of type 1 diabetes NexImmune, Inc. (Nasdaq: NEXI), Yale and JDRF have begun a two-year project to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells. The $600,000 grant,... Read More
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the appointment of Leena Gandhi, M.D., Ph.D., Director for the Center of Therapeutic Innovation at Dana-Farber Cancer Institute, to its Board of Directors as a Non-Executive Director. “I am... Read More
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a preclinical research collaboration with Columbia University Irving Medical Center’s (CUIMC) Herbert Irving Comprehensive Cancer Center (HICCC). The research will focus on the use of... Read More
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Mathias Oelke, Ph.D., has been promoted to Chief Scientific Officer. Dr. Oelke is a scientific co-founder of NexImmune and joined NexImmune in 2014. "We are excited to announce Mathias’... Read More
NexImmune, Inc. (Nasdaq: NEXI) and Zephyr AI (Zephyr) today announced a strategic partnership focusing on the discovery and validation of novel targets for new T-cell-mediated therapies in oncology. Combining Zephyr’s proprietary artificial intelligence (AI) and algorithmic technology with NexImmune’s Artificial Immune Modulation (AIM) nanoparticle technology, the collaboration will seek to identify and validate optimal... Read More
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a research and evaluation collaboration with The Laura and Isaac Perlmutter Cancer Center, a National Cancer Institute designated Comprehensive Cancer Center and part of NYU Langone Health.... Read More
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Kristi Jones, Chief Executive Officer, will present at the Barclays 2022 Global Healthcare Conference on Thursday, March 17, 2022 at 8:30 a.m. Eastern Time. The webcast will be... Read More
Clinical data updates for the Company’s two lead product candidates in Phase 1/2 clinical trials expected in 2H22 Investigational New Drug (IND) submission for NEXI-003, the Company’s first product for solid tumors, planned for 1H22 Plans to report additional preclinical and IND enabling data for the AIM Injectable platform throughout 2022 Completed successful $126.5M initial public offering (IPO) in February 2021; proceeds... Read More
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Kristi Jones has been appointed as the Company’s Chief Executive Officer and a member of its Board of Directors. Her appointment follows the departure of Scott Carmer, who submitted his... Read More
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will participate in the LLS TAP panel discussion entitled “Expanding the Possible with Next Generation Cell Therapies” on Friday, January 21, 2022... Read More
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the formation of its Autoimmune and Infectious Disease Scientific Advisory Board (AI & ID SAB). The AI & ID SAB is comprised of distinguished academic and industry leaders in the fields of... Read More
Initial Phase 1/2 data presented at the 63 rd American Society of Hematology (ASH) Annual Meeting and Exposition Phase 1/2 study of NEXI-002 as a monotherapy in patients with relapsed/refractory multiple myeloma patients who have failed ≥3 prior lines of therapy is ongoing NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted... Read More
Advancing two lead product candidates in Phase 1/2 clinical trials Additional clinical and preclinical data anticipated by year end 2021 and first half 2022 Announced collaboration with Yale University Department of Immunobiology to explore use of AIM INJ in regard to regulation of Type 1 Diabetes NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to... Read More
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced it plans to report third quarter financial results and provide a corporate update on Friday, November 12, 2021, via press release, prior to the market open. The press release will be... Read More
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that two abstracts have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 36 th Annual Meeting in Washington, D.C., being held November 10-14,... Read More
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will present at the 2021 Cantor Virtual Global Healthcare Conference Wednesday, September 29, 2021 at 2:00 PM Eastern time. The webcast will be... Read More
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will participate in a fireside chat during the Morgan Stanley 19th Annual Global Healthcare Conference today, September 10, 2021 at 1:15p.m.... Read More
Announcing first solid tumor indication in HPV associated-malignancies – NEXI-003 Advancing two lead product candidates in Phase 1/2 clinical trials Additional clinical and preclinical data anticipated in the second half of 2021 NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of... Read More
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a collaboration with Yale University’s Department of Immunobiology. The collaboration will focus on the use of NexImmune’s direct injection, artificial antigen presenting cells (AIM INJ)... Read More
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced it plans to report second quarter financial results and provide a corporate update on Monday, August 9, 2021, via press release, after market close. The press release will be accessible... Read More
Dr. Jack A. Ragheb as Senior Vice President, Translational Science Matt Schiller, Head of Business Development NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Jack A. Ragheb, MD, PhD, has been appointed to the newly created position... Read More
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will present a company overview at the virtual 2021 Human Health Innovation Conference on Tuesday, June 22, 2021 at 9:20 a.m. Eastern time. The... Read More
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the formation of its Scientific Advisory Board (SAB). The SAB is comprised of distinguished academic leaders in the fields of immuno-oncology, immunology and T cell biology and their... Read More
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that clinical data from its Phase 1/2 dose escalation study of NEXI-001 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting being... Read More
Advancing two lead product candidates in Phase 1/2 clinical trials Completed successful $126M initial public offering (IPO) in February 2021 Additional clinical and preclinical data anticipated in the second half of 2021 NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of... Read More
Mr. Rubin most recently served as Managing Director, Co-Head Life Sciences for Solebury Trout NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Chad Rubin has been appointed to the newly created position of Senior Vice President,... Read More
In 2020, advanced two product candidates into Phase 1/2 clinical trials while strengthening Board of Directors and management team Completed successful $126M initial public offering (IPO) in February 2021 to fund continuing operations through the second quarter of 2022 Additional clinical and preclinical data anticipated in the second half of 2021 NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company... Read More
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will present a company overview at the virtual 2021 Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 10:55 a.m. Eastern time.... Read More
Rapha Capital Management, LLC ( https://raphacap.com ), an investment management firm located in Miami, Florida , is pleased to announce that on February 17, 2021, its portfolio company, NexImmune, Inc. ("NexImmune"), closed an upsized initial public offering raising gross proceeds, before deducting underwriting discounts and commissions and offering expenses, of approximately $126.5 million. The gross proceeds included the... Read More
Barer & Son Capital, a life science venture capital fund managed by Hibiscus Capital Management, is pleased to announce that on February 17, 2021 , its portfolio company, NexImmune, Inc. ("NexImmune"), closed an upsized initial public offering raising gross proceeds, before deducting underwriting discounts and commissions and offering expenses, of approximately $126.5 million . The gross proceeds included the exercise in... Read More
C4 Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB